Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Burning Rock Biotech Ltd

Current price
0.82 USD +0.023 USD (+2.90%)
Last closed 0.83 USD
Sector Healthcare
Industry Diagnostics & Research
Exchange NASDAQ
Capitalization 85 117 576 USD
Yield for 12 month -65.84 %
21.11.2021 - 28.11.2021

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China. Address: No. 5, Xingdao Ring Road North, Guangzhou, China, 510005


WallStreet Target Price

3.99 USD

P/E ratio

Dividend Yield

Current Year

+79 643 382 USD

Last Year

+71 813 066 USD

Current Quarter

+18 038 179 USD

Last Quarter

+20 682 692 USD

Current Year

+53 738 546 USD

Last Year

+51 491 233 USD

Current Quarter

+12 149 321 USD

Last Quarter

+14 199 943 USD

Key Figures BNR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -542 585 728 USD
Operating Margin TTM -140.17 %
PE Ratio
Return On Assets TTM -31.08 %
PEG Ratio
Return On Equity TTM -65.47 %
Wall Street Target Price 3.99 USD
Revenue TTM 558 587 008 USD
Book Value 8.43 USD
Revenue Per Share TTM 5.46 USD
Dividend Share
Quarterly Revenue Growth YOY -17.5 %
Dividend Yield
Gross Profit TTM 380 039 000 USD
Earnings Share -0.97 USD
Diluted Eps TTM -0.97 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin -126.7 %

Dividend Analytics BNR

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BNR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:3
Payout Ratio
Last Split Date 01.08.2014
Dividend Date

Stock Valuation BNR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.2669
Price Sales TTM 0.1524
Enterprise Value EBITDA 0.0031
Price Book MRQ 0.6968

Financials BNR

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators BNR

For 52 weeks

0.82 USD 3.8 USD
50 Day MA 0.97 USD
Shares Short Prior Month 512 699
200 Day MA 1.99 USD
Short Ratio 9.78
Shares Short 475 959
Short Percent 0.54 %